
Nordicus Partners Corporation (NORD)
Last updated: 2026-11-05 16:35:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Nordicus Partners Corporation (NORD) operates in the SERVICES-MANAGEMENT CONSULTING SERVICES sector and is listed on NASDAQ. The stock is currently priced at $3.21, with a market capitalization of $79.72M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.48 to $5.15. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$79.72M | |
$3.88 | |
$331.50 | |
$1.25 | |
$3.73 | |
5.11K | |
7.03K | |
-- | |
$5.15 | |
$1.48 | |
-- | |
-- |
Nordicus Partners Corporation (NORD) Stock Price Today
Nordicus Partners Corporation (NORD) is currently trading at $3.21 as of 2026-11-05 16:16:00, down 13.96% ($0.52) from the previous close of $3.73
During today's regular trading session, NORD has traded between $1.25 and $331.50, with a trading volume of 5.11K shares. The current price is near the lower end of today's range.
Nordicus Partners Corporation (NORD) 7-Day Stock Price Change
Over the past seven days, Nordicus Partners Corporation (NORD) moved from $4.00 to $3.21, representing a decline of 19.88% ($0.79).
The stock traded between $3.21 and $5.15 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 34.09 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
NORD 52-Week Price Position
Position in Range: 47.0%
NORD is currently trading at $3.21, placing it 47.0% of the way from its 52-week low of $1.48 to its 52-week high of $5.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Nordicus Partners Corporation (NORD)?
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.
Nordicus Partners Corporation Information
| Industry | SERVICES-MANAGEMENT CONSULTING SERVICES |
| Exchange | NASDAQ |
| Company Website |
How to Buy Nordicus Partners Corporation (NORD) Stock on MEXC
Eligible investors can buy real shares of Nordicus Partners Corporation (NORD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Nordicus Partners Corporation (NORD) stock price today?
2.Is NORD stock going up or down today?
3.What is NORD pre-market price?
4.What is NORD after-hours price?
5.Is NORD stock trading now?
6.Where does NORD sit relative to its 52-week high and low?
7.What sector is Nordicus Partners Corporation in?
8.What is Nordicus Partners Corporation's market capitalization and where is it listed?
9.How is NORD valued in terms of P/E ratio and EPS?
10.Does Nordicus Partners Corporation pay a dividend?
Explore More US Stocks
Search Stocks
NORD Stock Calculator
Estimate the value between NORD shares and USD.
NORD Shares to USD
1.00 NORD shares = 3.205 USD
Calculations are estimates based on the latest available price and are for reference only.

